Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma
Authors:
- Josep CorominasJCJosep Corominas
- Victor SapenaVSVictor Sapena
- Marco Sanduzzi-ZamparelliMSMarco Sanduzzi-Zamparelli
- Cristina MillánCMCristina Millán
- Esther SamperESEsther Samper
- Neus LlarchNLNeus Llarch
- Gemma IserteGIGemma Iserte
- Ferràn TorresFTFerràn Torres
- Leonardo G. Da FonsecaLFLeonardo G. Da Fonseca
- Sergio Muñoz-MartínezSMSergio Muñoz-Martínez
- Alejandro FornerAFAlejandro Forner
- Jordi BruixJBJordi Bruix
Open Access
Abstract
Advanced hepatocellular carcinoma patients treated with sorafenib who develop early dermatologic adverse events (eDAEs) have a better prognosis. This may be linked to immune mechanisms, and thus, it is relevant to assess the association between peripheral immunity and the probability of developing eDAEs. Peripheral blood mononuclear cells of 52 HCC patients treated with sorafenib were analyzed at baseline and throughout the first eight weeks of therapy. T, B, Natural Killer cells, and their immune checkpoints expression data were characterized by flow cytometry. Cytokine release and immune-suppression assays were carried out ex vivo. Cox baseline and time-dependent regression models were applied to evaluate the probability of increased risk of eDAEs. DNAM-1, PD-1, CD69, and LAG-3 in T cells, plus CD16 and LAG-3 in NK cells, are significantly associated with the probability of developing eDAEs. While NK DNAM-1+ cells express activation markers, T DNAM-1+ cells induce immune suppression and show immune exhaustion. This is the first study to report an association between immune checkpoints expression in circulating immune cells and the increased incidence of eDAEs. Our results support the hypothesis for an off-target role of sorafenib in immune modulation. We also describe a novel association between DNAM-1 and immune exhaustion in T cells.Keywords
Funding Information
- Fundación Científica Asociación Española Contra el Cáncer (PI044031)
- Instituto de Salud Carlos III (FI19/00222, PI18/0768, PI15/00145, PI18/00542)
This publication has 49 references indexed in Scilit:
- Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenibJournal of Hepatology, 2014
- Cutting Edge: DNAX Accessory Molecule 1–Deficient CD8+ T Cells Display Immunological Synapse Defects That Impair Antitumor ImmunityThe Journal of Immunology, 2014
- T-Bet and Eomes Regulate the Balance between the Effector/Central Memory T Cells versus Memory Stem Like T CellsPLOS ONE, 2013
- Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF‐beta signalJournal of Surgical Oncology, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- The Transcription Factors T-bet and Eomes Control Key Checkpoints of Natural Killer Cell MaturationImmunity, 2012
- Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of CancerCancer Research, 2010
- Sorafenib inhibits the shedding of major histocompatibility complex class I–related chain A on hepatocellular carcinoma cells by down‐regulating a disintegrin and metalloproteinase 9†Hepatology, 2010
- Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylationLeukemia, 2008
- Activation, coactivation, and costimulation of resting human natural killer cellsImmunological Reviews, 2006